360 Financial Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,637 shares of the company’s stock after selling 223 shares during the period. 360 Financial Inc.’s holdings in Johnson & Johnson were worth $642,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in JNJ. EagleClaw Capital Managment LLC increased its stake in Johnson & Johnson by 2.0% during the 3rd quarter. EagleClaw Capital Managment LLC now owns 17,516 shares of the company’s stock valued at $2,824,000 after buying an additional 337 shares during the period. Dark Forest Capital Management LP acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $102,000. Balyasny Asset Management LLC grew its stake in shares of Johnson & Johnson by 70.4% in the 3rd quarter. Balyasny Asset Management LLC now owns 586,748 shares of the company’s stock worth $94,760,000 after purchasing an additional 242,366 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Johnson & Johnson by 290.7% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company’s stock worth $47,000 after purchasing an additional 218 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its stake in shares of Johnson & Johnson by 780.2% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 51,049 shares of the company’s stock worth $8,244,000 after purchasing an additional 45,249 shares during the last quarter. 68.78% of the stock is currently owned by hedge funds and other institutional investors.
JNJ stock opened at $179.66 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The stock has a market cap of $472.76 billion, a P/E ratio of 24.21, a P/E/G ratio of 3.42 and a beta of 0.66. The firm has a 50 day simple moving average of $177.65 and a 200 day simple moving average of $173.20. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69.
The business also recently declared a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were issued a dividend of $1.13 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 annualized dividend and a dividend yield of 2.52%. The ex-dividend date of this dividend was Monday, May 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 60.92%.
JNJ has been the topic of several recent research reports. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Daiwa Capital Markets initiated coverage on shares of Johnson & Johnson in a research note on Wednesday. They issued an “outperform” rating on the stock. Bank of America began coverage on shares of Johnson & Johnson in a research note on Wednesday, March 2nd. They issued a “neutral” rating on the stock. Raymond James lifted their target price on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Finally, Morgan Stanley dropped their target price on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 6th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $190.50.
In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William Hait sold 29,699 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the completion of the sale, the insider now owns 80,236 shares of the company’s stock, valued at $14,729,724.88. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 78,161 shares of company stock valued at $13,895,302. 0.35% of the stock is currently owned by corporate insiders.
Johnson & Johnson Profile (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Ciena Stock Giving Window of Opportunity
- Are These Cheap Copper Stocks Right For Your Portfolio?
- Zai Lab Stock Has Fallen to Value Levels
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.